For the Inventor, By the Inventor

Enter assignee name

La Jolla, CA, United States of America

Epicentrx, Inc.

Calculating rank

USPTO Granted Patents = 29

EPO Patents = 5

Forward Citations = 148

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Bryan T Oronsky (25 out of 29 patents)

Tony R Reid (12 out of 27 patents)

Jan Scicinski (10 out of 12 patents)

4. Christopher Larson (9 out of 13 patents)

5. Susan Knox (5 out of 13 patents)

6. Shoucheng Ning (4 out of 8 patents)

7. Louis F Cannizzo (4 out of 21 patents)

8. Scott Caroen (4 out of 4 patents)

9. Stephen P Velarde (3 out of 16 patents)

10. Kirstin F Warner (3 out of 15 patents)

11. Robert B Wardle (3 out of 14 patents)

12. Mark David Bednarski (3 out of 16 patents)

13. Arnold L Oronsky (2 out of 3 patents)

14. Neil C Oronsky (1 out of 3 patents)

15. Frans A Kuypers (1 out of 6 patents)

Core Competencies:

Oncolytic Adenovirus

Cancer Vaccines

Immunomodulatory Proteins

Recombinant Adenoviruses

Radioprotection Therapy

Medication Infusion Devices

Cyclic Nitro Compounds

Transgene Delivery

Glioma Treatment

Therapeutic Compositions

Organonitro Compounds

Parenteral Administration

29 patents: Sort by Forward Citations

1. 12357608 - Methods and compositions utilizing RRx-001 combination therapy for radioprotection (2025-07-15),

2. 12357607 - Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (2025-07-15),

3. 12295976 - Personalized cancer vaccines (2025-05-13),

4. 12291726 - A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoter (2025-05-06),

5. 12280123 - Recombinant adenoviruses carrying transgenes (2025-04-21),

6. 12109348 - Medication infusion devices, systems, and methods (2024-10-08),

7. 12054530 - Immunomodulatory fusion proteins (2024-08-06),

8. 12048793 - Medication infusion devices, systems, and methods (2024-07-30),

9. 12036247 - Multiple transgene recombinant adenovirus (2024-07-16),

10. 11999973 - Method for producing recombinant oncolytic adenovirus with modified E1a cancer-specific promoter (2024-06-04),

11. 11925617 - Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof (2024-03-12),

12. 11834492 - Human IL-10 receptor alpha fusion proteins (2023-12-05),

13. 11744859 - Compositions and methods for parenteral administration of therapeutic agents (2023-09-05),

14. 11701351 - Treatment of gliomas using organonitro compound combination therapy (2023-07-18),

15. 11660286 - Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products (2023-05-30),

Company Overview

Epicentrx, Inc. is a biotechnology company based in La Jolla, California, focused on developing innovative therapies for cancer treatment. The organization specializes in harnessing the power of the immune system to create targeted therapies that aim to improve patient outcomes. With a commitment to advancing cancer care, Epicentrx is engaged in cutting-edge research and development, leveraging its expertise in immuno-oncology to address unmet medical needs in the oncology landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

29 Patents

#22 in La Jolla, CA

#2,768 in California

#11,600 in US

#22,581 in the World

La Jolla, CA, United States of America

Epicentrx, Inc.

Forward Citations = 148

26 inventors:

Bryan T Oronsky (25 out of 29 patents)

Tony R Reid (12 out of 27 patents)

Jan Scicinski (10 out of 12 patents)

4. Christopher Larson (9 out of 13 patents)

5. Susan Knox (5 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Epicentrx, Inc.. Retrieved from https://idiyas.com/company/epicentrx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…